Therefore, as an alternative, a human EGFR-expressing mouse oral squamous cell cancer model, mEERL-hEGFR, human EGFR-expressing murine oropharyngeal cancer cell, was established and was used for combination therapy of human EGFR-targeted NIR-PIT with CD25-targetd NIR-PIT [47], which is exactly the regimen that is planned for a clinical trial. This evidence concerns the gene EGFR and oropharynx cancer.